Advances inbiotechnology have enabled the identification of several novel biomarkers,which are presently being used for a variety of purposes, including diagnosis,drug development, clinical research and to facilitate therapy-related decisions
The report features anextensive study of the current landscape and future outlook of theimmuno-oncology biomarkers testing market (focusing particularly on TMB, MSIand TILs (CD3+, CD4+, CD8+, FOXP3+)). It provides an in-depth analysis,highlighting the capabilities of the various companies engaged in this domain. Amongstvarious elements, the report includes:
§ A detailed analysisof ongoing, biomarker-based clinical trials initiated by big pharmaceuticalcompanies.
§ An analysis of thelandscape of companies offering testing services for cancer biomarkers, namelyTMB, MSI / MMR and TILs (including CD3+, CD4+, CD8+ and FOXP3+).
§ An insightful 2X2representation of the results of a detailed competitiveness analysis of varioustests (segregated across different biomarkergroups).
§ Elaborate profiles ofleading analytical testing service providers focused on immuno-oncologybiomarkers (shortlisted based on strengthof service portfolio).
§ A detailedpublication analysis of over 180 research articles that have been publishedsince 2016, highlighting the key focus areas of ongoing research activityrelated to immuno-oncology biomarkers, namely TMB, MSI / MMR and TILs.
§ A comprehensiveclinical trial analysis of completed, ongoing and planned studies, focused onthe assessment of cancer biomarkers, namely TMB, MSI / MMR and TILs.
§ A discussion on theupcoming opportunities that are likely to impact the evolution of this marketover the coming years.
§ A discussion onvarious steps involved in development operations of companion diagnostics
§ A comparativeanalysis of the needs of different stakeholders involved in the development ofcompanion diagnostic products
§ A detailed market forecast, featuring analysis of thecurrent and projected future opportunity across key market segments (listedbelow)
- Type of test
§ Laboratory DevelopedTests (LDTs)
§ Companion DiagnosticTests (CDx)
- Type of disease indication
§ Breast cancer
§ Blood cancer
§ Colon / Colorectalcancer
§ Lung Cancer
§ Prostate Cancer
- Type of cancer biomarker
§ MSI / MMR
- Type of analytical technique
§ Next GenerationSequencing (NGS)
§ Polymerase ChainReaction (PCR)
- Key geographical regions
§ North America
Keycompanies covered in the report
§ Foundation Medicine
§ Personal GenomeDiagnostics
§ Dr Lal PathLabs
§ Shenzhen YuceBiotechnology
Formore information please click on the following link:
1. Global T-Cell (CAR-T,TCR, and TIL) Therapy Market (4th Edition), 2019-2030
2. Neoantigen TargetedTherapies Market, 2019-2030
3. Companion DiagnosticsMarket (2nd Edition), 2019-2030
4. Cell Encapsulation: Focus onTherapeutics and Technologies, 2019-2030
5. In Vitro ADME TestingServices Market, 2019-2030
About Roots Analysis
Roots Analysis is one of the fastest growingmarket research companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at firstname.lastname@example.org
Roots Analysis Private Limited
+1 (415) 800 3415